Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

BID Cleavage Pattern Is a Novel Check-Point That Determines the Fate of Human Erythroid Progenitors (Differentiation or Apoptosis

Mathilde Lamarque, MD, Flavia Guillem, PhD, Zakia Belaid, PhD, Olivier Hermine, MD PhD, Genevieve Courtois, PhD

Blood (2016) 128 (22): 397.

https://doi.org/10.1182/blood.V128.22.397.397

Published: 2016

Journal Articles

XPO1 (Exportin-1) Is a Major Regulator of Human Erythroid Differentiation. Potential Clinical Applications to Decrease Ineffective Erythropoiesis of Beta-Thalassemia

Flavia Guillem, PhD, Michael Dussiot, PhD, Sebastien Causse, PhD, Guillaume Marcion, Emilie-Fleur Gautier, PhD, Julien Rossignol, MD, Jean benoit Arlet, MD PhD, Mathilde Lamarque, MD, Patrick Mayeux, PhD, Frederique Verdier, PhD, Xiuli An, MD PhD, Jean-Antoine Ribeil, MD PhD, Carmen Garrido, PhD, Genevieve Courtois, PhD, Narla Mohandas, D.Sc., Olivier Hermine

Blood (2015) 126 (23): 2368.

https://doi.org/10.1182/blood.V126.23.2368.2368

Published: 2015

Journal Articles

The Spectrum Of Cold Agglutinin Disease At The Era Of Rituximab: A Retrospective Study On 48 Patients

Mathilde Lamarque, MD, Véronique Leblond, MD, PhD, Bruno R. Varet, MD, Sylvain Choquet, MD, Jean Paul Vernant, MD, Richard Delarue, MD, Bertrand Godeau, MD, Olivier Hermine, MD, PhD, Marc Michel, IV

Blood (2013) 122 (21): 2193.

https://doi.org/10.1182/blood.V122.21.2193.2193

Published: 2013

Journal Articles

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Lionel Ades, MD, PhD, Mathilde Lamarque, MD, Sophie Raynaud, Raphael Itzykson, Sylvain Thepot, Bruno Quesnel, MD, PhD, Francois Dreyfus, Odile Beyne Rauzy, MD, PhD, Pascal Turlure, MD, Norbert Vey, MD, Christian Recher, MD, Caroline Dartigeas, MD, Laurence Legros, MD, PhD, Jacques Delaunay, MD, Sorin Visanica, Aspasia Stamatoullas, Pierre Fenaux, MD, PhD

Blood (2012) 120 (21): 422.

https://doi.org/10.1182/blood.V120.21.422.422

Published: 2012

Journal Articles

Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Mathilde Lamarque, MD, Sophie Raynaud, Raphael Itzykson, MD, Sylvain Thepot, Bruno Quesnel, Francois Dreyfus, Odile Beyne Rauzy, Pascal Turlure, Norbert Vey, MD, Christian Recher, MD, PhD, Caroline Dartigeas, MD, Laurence Legros, Jacques Delaunay, Sorin Visanica, Aspasia Stamatoullas, Pierre Fenaux, MD, PhD, Lionel Ades

Blood (2011) 118 (21): 972.

https://doi.org/10.1182/blood.V118.21.972.972

Published: 2011

NARROW

BID Cleavage Pattern Is a Novel Check-Point That Determines the Fate of Human Erythroid Progenitors (Differentiation or Apoptosis

XPO1 (Exportin-1) Is a Major Regulator of Human Erythroid Differentiation. Potential Clinical Applications to Decrease Ineffective Erythropoiesis of Beta-Thalassemia

The Spectrum Of Cold Agglutinin Disease At The Era Of Rituximab: A Retrospective Study On 48 Patients

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Email alerts

ASH Publications

American Society of Hematology

BID Cleavage Pattern Is a Novel Check-Point That Determines the Fate of Human Erythroid Progenitors (Differentiation or Apoptosis

XPO1 (Exportin-1) Is a Major Regulator of Human Erythroid Differentiation. Potential Clinical Applications to Decrease Ineffective Erythropoiesis of Beta-Thalassemia

The Spectrum Of Cold Agglutinin Disease At The Era Of Rituximab: A Retrospective Study On 48 Patients

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only